Here's why Viking Therapeutics, Cambrex, and Sarepta Therapeutics are all solid biotech plays this month.
News & Analysis: Cambrex
CBM earnings call for the period ending December 31, 2018.
Shares dropped after the company reported mixed earnings.
CBM earnings call for the period ending September 30, 2018.
Adding these biotech stocks to portfolios at current prices could pay off.
It could be the perfect time to add shares in these biotech companies to portfolios ahead of key catalysts.
Want to cash in on the life sciences boom? Here are three stocks to check out.
Investors looking for cheap stocks to buy right now should consider General Electric, Kinder Morgan, and Cambrex Corporation.
The company announced an 8% rise in quarterly revenue and a 73% increase in cash compared to June, and raised its full-year 2016 guidance.
Cambrex Corporation manufactures active pharmaceutical ingredients for dozens of therapeutics used everyday. You could say it’s having a pretty good run.